Van De Stadt E, Yaqub M, Jahangir AA, Hendrikse H, Bahce I (2022) Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients—an overview. Front Oncol 12. https://doi.org/10.3389/fonc.2022.900450

Article  PubMed  Google Scholar 

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics, CA: a cancer. J Clin 61(2):69–90. https://doi.org/10.3322/caac.20107

Article  Google Scholar 

Qiu B, Cai K, Chen C, Chen J, Chen K-N, Chen Q-X, Cheng C, Dai T-Y, Fan J, Fan Z, Hu J, Hu W-D, Huang Y-C, Jiang G-N, Jiang J, Jiang T, Jiao W-J, Li H-C, Li Q, Liao Y-D, Liu H-X, Liu J-F, Liu L, Liu Y, Long H, Luo Q-Q, Ma H-T, Mao N-Q, Pan X-J, Tan F, Tan L-J, Tian H, Wang D, Wang W-X, Wei L, Wu N, Wu Q-C, Xiang J, Xu S-D, Yang L, Zhang H, Zhang L, Zhang P, Zhang Y, Zhang Z, Zhu K, Zhu Y, Um S-W, Oh I-J, Tomita Y, Watanabe S, Nakada T, Seki N, Hida T, Sasada S, Uchino J, Sugimura H, Dermime S, Cappuzzo F, Rizzo S, Cho WC-S, Crucitti P, Longo F, Lee KY, Ruysscher DD, Vanneste BGL, Furqan M, Sieren JC, Yendamuri S, Merrell KW, Molina JR, Metro G, Califano R, Bongiolatti S, Provencio M, Hofman P, Gao S, He J (2021) Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. Transl Lung Cancer Res 10(9):3713–3736. https://doi.org/10.21037/tlcr-21-634

Article  CAS  PubMed  PubMed Central  Google Scholar 

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S (2018) Metastatic non-small cell lung cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:iv192. https://doi.org/10.1093/annonc/mdy275

Article  CAS  PubMed  Google Scholar 

Wu Y-L, Lee JS, Thongprasert S, Yu C-J, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen Y-M, Sun Y, Margono B, Fuerte F, Chang G-C, Seetalarom K, Wang J, Cheng A, Syahruddin E, Qian X, Ho J, Kurnianda J, Liu HE, Jin K, Truman M, Bara I, Mok T (2013) Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol 14(8):777–786. https://doi.org/10.1016/s1470-2045(13)70254-7

Article  CAS  PubMed  Google Scholar 

Mithoowani H, Febbraro M (2022) Non-small-cell Lung Cancer in 2022: a review for general practitioners in Oncology. Curr Oncol 29(3):1828–1839. https://doi.org/10.3390/curroncol29030150

Article  PubMed  PubMed Central  Google Scholar 

Ettinger WD, Aisner DS, Akerley DL, Bauman W, Chirieac J, D’Amico LR, DeCamp TA, Dilling MM, Dobelbower TJ, Doebele M, Govindan RC, Gubens R, Hennon MA, Horn M, Komaki L, Lackner R, Lanuti RP, Leal M, Leisch TA, Lilenbaum LJ, Lin R, Loo J, Martins BW Jr, Otterson R, Reckamp GA, Riely K, Schild GJ, Shapiro SE, Stevenson TA, Swanson J, Tauer SJ, Yang K, Gregory SC, Hughes K (2017) Non-small Cell Lung Cancer, Version 5.2017, NCCN clinical practice guidelines in Oncology. J Natl Compr Canc Netw 15(4):504–535. https://doi.org/10.6004/jnccn.2017.0050

Article  PubMed  Google Scholar 

Zhang Q, Wang R, Xu L (2023) Clinical advances in EGFR-TKI combination therapy for EGFR-mutated NSCLC: a narrative review. Translational Cancer Res 12(12):3764–3778. https://doi.org/10.21037/tcr-23-956

Article  CAS  Google Scholar 

Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS (1997) Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 8(12):1197–1206. https://doi.org/10.1023/A:1008209720526

Article  CAS  PubMed  Google Scholar 

Rosenkranz AA, Slastnikova TA (2020) Epidermal growth factor receptor: key to selective intracellular delivery. Biochem (Moscow) 85(9):967–993. https://doi.org/10.1134/s0006297920090011

Article  CAS  Google Scholar 

Habban Akhter M, Sateesh Madhav N, Ahmad J (2018) Epidermal growth factor receptor based active targeting: a paradigm shift towards advance tumor therapy. Artif Cells Nanomed Biotechnol 46(Sup2):1188–1198. https://doi.org/10.1080/21691401.2018.1481863

Article  CAS  PubMed  Google Scholar 

Liu XM, Wang P, Zhang CY, Ma ZL (2017) Epidermal growth factor receptor (EGFR): a rising star in the era of precision medicine of lung cancer. Oncotarget 8(30):50209–50220. https://doi.org/10.18632/oncotarget.16854

Article  PubMed  PubMed Central  Google Scholar 

Gahr S, Stoehr R, Geissinger E, Ficker JH, Brueckl WM, Gschwendtner A, Gattenloehner S, Fuchs FS, Schulz C, Rieker RJ, Hartmann A, Ruemmele P, Dietmaier W (2013) EGFR mutational status in a large series of caucasian European NSCLC patients: data from daily practice. Br J Cancer 109(7):1821–1828. https://doi.org/10.1038/bjc.2013.511

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mok WY, Thongprasert TS, Yang S, Chu CH, Saijo DT, Sunpaweravong N, Han P, Margono B, Ichinose B, Nishiwaki Y, Ohe Y, Yang Y, Chewaskulyong JJ, Jiang B, Duffield H, Watkins EL, Armour CL, Fukuoka AA (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947–957. https://doi.org/10.1056/NEJMoa0810699

Article  CAS  PubMed  Google Scholar 

Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121–128. https://doi.org/10.1016/s1470-2045(09)70364-x

Article  CAS  PubMed  Google Scholar 

Meador CB, Sequist LV, Piotrowska Z (2021) Targeting EGFRExon 20 insertions in non–small cell Lung Cancer: recent advances and clinical updates. Cancer Discov 11(9):2145–2157. https://doi.org/10.1158/2159-8290.Cd-21-0226

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zheng Y-D, Zhang H, Zhan Y, Bian Y-C, Ma S, Gan H-X, Lai X-J, Liu Y-Q, Gong Y-C, Liu X-F, Sun H-B, Li Y-G, Zhong D-F, Miao L-Y, Diao X-X (2020) Pharmacokinetics, mass balance, and metabolism of [14C]vicagrel, a novel irreversible P2Y12 inhibitor in humans. Acta Pharmacol Sin 42(9):1535–1546. https://doi.org/10.1038/s41401-020-00547-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ge X, Ma S, Yan S, Wu Y, Chen C, Tang C, Zhan Y, Bian Y-c, Shen K, Feng S, Gao X, Zhong D, Zhang H, Miao L-Y, Diao X-X (2023) Mass balance study of [14C]SHR0302, a selective and potent JAK1 inhibitor in humans. Xenobiotica 53(2):69–83. https://doi.org/10.1080/00498254.2023.2176267

Article  CAS  PubMed  Google Scholar 

Pusalkar S, Zhou X, Li Y, Cohen L, Yang JJ, Balani SK, Xia C, Shyu WC, Lu C, Venkatakrishnan K, Chowdhury SK (2020) Biotransformation pathways and metabolite profiles of oral [14C]Alisertib (MLN8237), an investigational aurora a kinase inhibitor, in patients with advanced solid tumors. Drug Metab Dispos 48(3):217–229. https://doi.org/10.1124/dmd.119.087338

Article  CAS  PubMed  PubMed Central  Google Scholar 

Prakash C, Fan B, Altaf S, Agresta S, Liu H, Yang H (2019) Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects. Cancer Chemother Pharmacol 83(5):837–848. https://doi.org/10.1007/s00280-019-03793-7

Article  CAS  PubMed  Google Scholar 

Yamada M, Mendell J, Takakusa H, Shimizu T, Ando O (2019) Pharmacokinetics, metabolism, and excretion of [14C]Esaxerenone, a novel mineralocorticoid receptor blocker in humans. Drug Metab Dispos 47(3):340–349. https://doi.org/10.1124/dmd.118.084897

Article  CAS  PubMed  Google Scholar 

Zhang H, Zhang D, Ray K, Zhu M (2009) Mass defect filter technique and its applications to drug metabolite identification by high-resolution mass spectrometry. J Mass Spectrom 44(7):999–1016. https://doi.org/10.1002/jms.1610

Article  CAS  PubMed  Google Scholar 

Zhang H, Ma L, He K, Zhu M (2008) An algorithm for thorough background subtraction from high-resolution LC/MS data: application to the detection of troglitazone metabolites in rat plasma, bile, and urine. J Mass Spectrom 43(9):1191–1200. https://doi.org/10.1002/jms.1432

Article  CAS  PubMed  Google Scholar 

FDA, CFR - Code of Federal Regulations Title 21–FOOD AND DRUGS (2022) https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=361&showFR=1, (Accessed 29 Nov.2022)

Bian Y, Zhang H, Ma S, Jiao Y, Yan P, Liu X, Ma S, Xiong Y, Gu Z, Yu Z, Huang C, Miao L (2020) Mass balance, pharmacokinetics and pharmacodynamics of intravenous HSK3486, a novel anaesthetic, administered to healthy subjects. Br J Clin Pharmacol 87(1):93–105. https://doi.org/10.1111/bcp.14363

Article  CAS  PubMed  Google Scholar 

Hop CECA, Wang Z, Chen Q, Kwei G (1998) Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 87(7):901–903. https://doi.org/10.1021/js970486q